Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-10T14:00:08.719Z Has data issue: false hasContentIssue false
  • English
  • Français

Resource use and costs associated with different states of breast cancer

Published online by Cambridge University Press:  01 April 2007

Mathias Lidgren ,
Nils Wilking ,
Bengt Jönsson  and
Clas Rehnberg
Mathias Lidgren
Affiliation:
Karolinska Institutet
Nils Wilking
Affiliation:
Karolinska Institutet
Bengt Jönsson
Affiliation:
Stockholm School of Economics
Clas Rehnberg
Affiliation:
Karolinska Institutet
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: This study investigated the direct medical resource use and cost, informal care cost, and indirect cost associated with breast cancer in different states of the disease in normal clinical practice.

Methods: A retrospective database analysis was used to estimate direct medical resource use and cost, and a patient questionnaire was used to evaluate informal care and work capacity in different states of breast cancer.

Results: For patients younger than 65 years of age, the first year after a primary diagnosis total cost amounted to 280,000 SEK ($39,000) and the first year after a local or contralateral recurrence total cost was 351,000 SEK ($48,900). The second and following years after primary breast cancer or recurrence had substantially lower total cost, amounting to 94,000 SEK ($13,000). For patients with metastatic disease, the annual total cost was estimated to 334,000 SEK ($46,500). For patients older than 65 years of age, the total cost for the first year after a primary diagnosis amounted to 80,000 SEK ($11,200) and the total cost for the first year after a local or contralateral recurrence was 92,000 SEK ($12,900). The total cost for the second and following years after primary breast cancer or recurrence was estimated to 18,000 SEK ($2,600), and the total annual cost for patients with metastatic was 122,000 SEK ($17,000).

Conclusions: Both direct medical costs and indirect cost vary substantially between disease states. For patients under 65 year of age, indirect costs accounted for more than 50 percent of the total cost.

Keywords

Resources useDirect costIndirect costInformal care costBreast cancer
Type
GENERAL ESSAYS
Information
International Journal of Technology Assessment in Health Care , Volume 23 , Issue 2 , April 2007 , pp. 223 - 231
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Bercez, C, Lebrun, T, Bonneterre, ME et al. , [Advanced breast cancer: An evaluation of the cost of recurrence]. Bull Cancer. 1999; 86: 585–590.Google ScholarPubMed
2.Bonneterre, J, Bercez, C, Bonneterre, ME, Lenne, X, Dervaux, B. Cost-effectiveness analysis of breast cancer adjuvant treatment: FEC 50 versus FEC 100 (FASG05 study). Ann Oncol. 2005; 16: 915–922.CrossRefGoogle ScholarPubMed
3.Bradley, CJ, Neumark, D, Bednarek, HL, Schenk, M. Short-term effects of breast cancer on labor market attachment: Results from a longitudinal study. J Health Econ. 2005; 24: 137–160.CrossRefGoogle ScholarPubMed
4.Delea, TE, Karnon, J, Smith, RE et al. , Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care. 2006; 12: 374–386.Google ScholarPubMed
5.Drummond, M, O'Brien, B, Stoddart, G, Torrance, G. Methods for the economic evaluation of health care programs. 2nd ed. Oxford: Oxford Medical Publications; 1997.Google Scholar
6.Elkin, EB, Weinstein, MC, Winer, EP et al. , HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol. 2004; 22: 854–863.CrossRefGoogle ScholarPubMed
7.Hodgson, TA, Meiners, MR. Cost-of-illness methodology: A guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982; 60: 429–462.CrossRefGoogle ScholarPubMed
8.Johannesson, M.Theory and methods of economic evaluation of health care: Dordrecht: Kluwer Academic Publisher; 1996.CrossRefGoogle ScholarPubMed
9.Lidgren, M, Wilking, N, Jönsson, B. Cost of breast cancer in Sweden 2002. Eur J Health Econ. In press.Google Scholar
10.Rao, S, Kubisiak, J, Gilden, D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004; 83: 25–32.CrossRefGoogle ScholarPubMed
11.Statistics Sweden. 2a-Average monthly salary by age, level of education, and sex in all sectors 2003. Statistical yearbook of salaries and wages 2003. Stockholm: Statistics Sweden; 2004.Google Scholar
12.Statistics Sweden. 184-Basic information and ratios for the service sector, sole proprietors excluded. Statistical Yearbook of Sweden 2006. Stockholm: Statistics Sweden; 2005.Google Scholar
13.Statistics Sweden. 331-Per cent of population in the labour force. Statistical Yearbook of Sweden 2006. Stockholm: Statistics Sweden; 2005.Google Scholar
14.Statistics Sweden. 365-Index numbers for direct wages for employees in the private sector,1st quarter 994=100. Statistical Yearbook of Sweden 2006. Stockholm: Statistics Sweden; 2005.Google Scholar
15.Statistics Sweden. 378-Total income from employment and business: Median values. Current prices. Statistical Yearbook of Sweden 2006. Stockholm: Statistics Sweden; 2005.Google Scholar
16.The National Board of Health and Welfare. Cancer incidence in Sweden 2004. Stockholm: Official Statistics of Sweden; 2005.Google Scholar
17.The National Board of Health and Welfare. Causes of death 2003. Stockholm: Official Statistics of Sweden; 2005.Google Scholar
18.Weinstein, M, Siegel, J, Gold, M, Kamlet, M, Russell, L. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996; 276: 1253–1258.CrossRefGoogle ScholarPubMed